Indication intelligence, analysis and sector perception

RMi Research Note: Capricor Therapeutics (CAPR) DUMP before the next big SLUMP!

December 31, 2025 1:09pm

Bigger declines are soon to come …

Timing will be everything until the FDA “speaks;” the higher CAPR rose from 12/2’s $6.36, the steeper the fall!

STICKING to my CONVICTION that Capricor Therapeutics (CAPR) is overbought and whose valuation is disconnected from fundamentals.

CAPR Wednesday (12/31) is down yet again -$0.56 or -1.93% to $28.40(1 p.m.) after, Tuesday’s -$1.08 to $28.96, Monday’s +$0.07, Friday’s -$0.27 and last Wednesday’s -$0.57) …

Doubts still abound re: regulatory fragility and marginal HOPE-3 results and valuation concerns remain a key hang-up!

CAPR remains a structurally challenged, chronically unprofitable company whose valuation is disconnected from fundamentals.
It has begun; timing will be everything!
The higher CAPR rises, the steeper the fall!

I also BELIEVE that the CEO forgot investors in delivering the announcement of P3 HOPE-3 study; letting the investment bankers know first as how quickly a public offering “evolved”?

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. Whether information or intelligence is good, bad, or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor, and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication. Regulation Analyst Certification (Reg AC):

The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and it’s or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.

35 companies, 1 interpreter!

Insight, foresight and recommendation

What's Happening Today

2 hours 1 min ago
RMi Research Note: Capricor Therapeutics (CAPR) DUMP before the next big SLUMP!

7 hours 6 min ago
RMi Pre-opening: It’s over

My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.

My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.

Do you have an opinion you would like to share with us? We would like to hear from you.

Please e-mail us at hwm@regmedinvestors.com.

Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors with past experience in sell-side analysis, buy-side management, corporate management and due diligence.

RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.

The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.

The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.